Professor R. Knox:
JOINT MEETING No. 1

Section of Pathology with Section of Medicine
Chairman-Professor G. PAYLING WRIGHT, D.M., F.R.C.P.
(President of the Section of Pathology) [December 10, 1952] DISCUSSION ON CHEMOTHERAPY OF TUBERCULOSIS [Abstract] Professor R. Knox:
Isoniazid: In Vitro Sensitivity and Resistance In the last few months we have been studying the sensitivity and resistance of M. tuberculosis and other mycobacteria to isoniazid. The work has been undertaken jointly with my colleagues Dr. Anderson, Dr. Collard, Dr. King and others, and I should like to mention a few of the salient points which we have established or which we are investigating.
(1) In Vitro Tests ofSensitivity and Resistance We have previously shown (Knox, King and Woodroffe, 1952) that when a set of tubes of Dubos liquid medium containing falling dilutions of isoniazid is inoculated with M. tuberculosis the endpoint shifts as incubation continues. We have shown that this shift in the end-point is the resultant of two factors-(i) inactivation of the drug which occurs even in uninoculated Dubos medium and (ii) the emergence of resistant organisms. The phenomenon of shift in the end-point could clearly be explained by either or both of these factors. If the drug were solely bacteriostatic then the growth which eventually occurred would be due to multiplication of the inoculated sensitive cells escaping from the influence of the drug as it became inactivated. If the drug were bactericidal to sensitive cells then the growth which eventually occurred would be due to multiplication of a few resistant cells which had survived in the inoculum. The truth probably is that both of these processes are important, and there is clearly a need for careful population studies on this problem. In the meantime it would seem that isoniazid in very high concentrations has a predominantly bactericidal action but is predominantly bacteriostatic in lower concentrations. The relative importance of the two effects will clearly depend on other factors besides drug concentration. We have evidence, for example, suggesting that sublethal concentrations of streptomycin increase the bactericidal effect; a similar increase in bactericidal efficiency is produced by increasing the temperature of growth . That this effect of temperature is biologically important is suggested by the results obtained by Goulding and Robson in experimental tuberculosis (Goulding and Robson, 1952) .
(2) The Value of In Vitro Techniques
We have developed a plate test using M. smegmatis as the test organism for investigations into the action of isoniazid and related drugs. A culture of M. smegmatis is heavily cultured on to the surface of an agar plate (using Dubos medium) and blotting-paper strips soaked in solutions of isoniazid or other substances under investigation are placed on the plate.
The smegma plate is useful for demonstrating: (a) The relative efficiency of different drugs. (e) Growth-stimulating substances. We have recently described this technique (King, Knox and Woodroffe, 1953) , which is essentially the auxanographic technique first used by Beyerinck (1889) and elaborated by' Pontecorvo (1949). (3) The Significance of Resistance We have found that a strain of H37Rv which had developed resistance to about 10-20 ,ug./ml. of isoniazid produced typical corneal lesions in experimental animals (Goulding, King, Knox and Robson, 1952) . These lesions did not respond to isoniazid. From patients with pulmonary tuberculosis whose clinical condition was deteriorating we have also isolated cultures of tubercle bacilli with similar in vitro resistance. On the other hand cultures from patients treated with isoniazid and streptomycin together have either proved negative or when positive have so far proved sensitive to both drugs after much longer periods of treatment. It looks therefore as though in vitro tests of resistance to isoniazid have some clinical significance, though the whole problem is complicated by various problems of bacterial nutrition.
(4) It is already established that isoniazid readily penetrates into tissues and cells. In this connexion it is well to remember that isoniazid has a smaller molecular weight than almost any other comparable drug. Its molecular weight of 137 compares, for example, with 172 for sulphanilamide, 323 for Chloromycetin, 334 for penicillin, 579 for streptomycin and about 200,000 for y-globulin. I should like to make a plea for thinking of these drugs in terms of molarity rather than in ,ug. per ml. or mg./.
(5) The outstanding fact about isoniazid is its remarkable specificity. We are engaged in studying its mode of action and hope that information derived from studies of the effect of isoniazid and of synergistic and antagonistic substances will give information about the exact biochemical lesion which it induces and so perhaps lead to the development of even more effective drugs.
Experimental Investigations in Intracorneal Infections Professor J. M. Robson said that he would restrict his communication to the use of corneal methods in the investigation of isoniazid given either alone or in combination with other drugs. The investigation described proved particularly interesting as it was proceeding at the same time as the clinical trials, the results being obtained rather more quickly than those of clinical experiments. It was thus possible to see to what extent the results obtained in animal experiments were, in fact, valid in man.
Professor Robson then gave a short description of the rabbit and mouse intra-corneal methods. He then continued: In both cases the organisms are injected actually into the cornea. In the case of the mouse the lesion develops to a maximum in about thirty days and then regresses somewhat. There is never any breakdown nor is there any systematic dissemination in the mouse and hence the animals are always safe to handle. In the rabbit the lesion is progressive, involving the whole of the cornea and spreading into the animal which ultimately dies from generalized tuberculosis. In both animals drugs can be given systematically either in the food or by injection; in addition, in the rabbit the drug can be injected into the vitreous, where a depot is formed; if both eyes are inoculated each animal can serve as its-own control.
Results in Mice
Isoniazid produces complete inhibition of corneal tuberculosis during the period of treatment, but after cessation of treatment lesions appear which become as extensive as in untreated animals. This result is similar to the one previously obtained with thiosemicarbazone and different from that obtained with streptomycin where there is some breakdown during treatment, but where protection also exists after cessation of treatment. Isoniazid in combination with streptomycin produces very striking effects; not only is there control during the period of treatment, but very little breakdown occurs after cessation of treatment. These results are in agreement with those obtained clinically.
When isoniazid is combined with PAS the results are no better than those obtained with isoniazid alone, i.e. there is severe breakdown after cessation of treatment.
Results in Rabbits
These are in rather striking contrast to those obtained in mice since treatment with isoniazid not only controlled the infection during the period of treatment, but there was no breakdown whatever after cessation of treatment. In contrast to this streptomycin produced only partial inhibition.
It is not clear why isoniazid should be so much more effective in the rabbit than in the mouse, particularly since the rabbit is less resistant to tuberculosis than the mouse. It has been found that the body temperature of the rabbit is several degrees higher than that of the mouse and this also applies to the corneal temperature in both species. It is possible that isoniazid is more effective at the higher temperature, and this question is being further investigated.
All this work has been carried out in collaboration with Dr. R. Goulding.
Dr. D. A. Mitchison:
Isoniazid Resistance In Vitro and In Vivo There are two techniques which have been widely used for testing the sensitivity of tubercle bacilli to chemotherapeutic agents. In one of these a culture on egg medium is obtained from sputum and the growth is then subcultured in Dubos Tween-albumin medium. The test is performed by inoculating from the Dubos medium into tubes of the same medium containing a range of drug concentrations. This method was found unsatisfactory with isonizaid since during subculture in Dubos medium 10 out of 16 strains were found to show a marked fall in the apparent degree of resistance (Mitchison, 1953) .
In the second technique part of the primary growth on egg medium is ground up with distilled water and a 3 mm. loopful of the resulting opalescent suspension is inoculated directly on to Lowenstein-Jensen slopes containing 0, 02, 1, 5, 10 and 50 pg. per ml. isoniazid (Medical Research Council, 1952 . This method is recommended for routine use. Dilution of the inoculum by 10to 100-fold, storage of the culture at 370, and subculture on Lowenstein-Jensen slopes, all tended to cause a fall in the apparent degree of resistance (Mitchison, 1953) , so that one should test primary cultures as soon as they become positive and the inoculum should be approximately equal in opacity to that of a ten-day Dubos culture.
Sensitive strains of tubercle bacilli were inhibited by 0-2 pg. per ml. isoniazid in Lowenstein-Jensen medium. When guinea-pigs and mice were infected with strains growing on 0-2 pg. per ml. but not on 1 pg. per ml., treatment with isoniazid at 20 mg. per kg. per day prevented the development of tuberculosis completely or in part (Barnet, Bushby and Mitchison, 1953a) . However, when these animals were infected with strains growing on 1 pg. per ml. or more the course of their experimental tuberculosis was not altered by treatment at the same dose level (Barnet, Bushby and Mitchison, 1953b Antituberculous Activity of Certain Non-ionic Detergents To date, successful chemotherapy of tuberculosis has depended, ultimately, on a direct action of the drug against the tubercle bacillus, a line of approach that has been so successful, in recent years, against the more acute bacterial infections. Yet the natural development of a tuberculous infection is dependent on a much more cqmplicated host-parasite inter-relationship than any of the acute infections. It is therefore surely more than idle speculation to suggest weighting the chemotherapy of tuberculosis towards enhancing the host defence mechanism rather than directly damaging the parasite. This possibility is strengthened by the successful use of calciferol in lupus vulgaris, where certainly the drug has no direct action against the tubercle bacillus, but may well enhance the specific cellular reaction to it. With these ideas in mind I shall outline the experimental results obtained with a non-ionic detergent.
This work started when we found, quite by chance, that a commercial non-ionic detergent Triton A20 produced a striking suppressive effect on the course of an acute tuberculous infection in the mouse (Cornforth, Hart, Rees and Stock, 1951) . It soon became apparent we were not dealing with a "chemotherapeutic" agent in the normally accepted meaning of the term, for it did not inhibit the growth of tubercle bacilli in the test tube; it, in fact, promoted dispersed growth in the depth of a fluid medium. Moreover, it was novel to have a non-ionic detergent, highly surface active, with antituberculous properties.
Our chemical colleagues Drs. Comforth and Stock synthesized an homologous series of non-ionic detergents having the general formula shown in Fig. 1 of which show similar anti-tuberculous activity but are less toxic than the commercial product. This series is made up of a number of similar units bridged by methylene groups. Each unit has a phenolic nucleus with a hydrocarbon substituent in the para position to the phenolic-OH, and this alkylsubstituted phenol (octyl phenol) constitutes the hydrophobic portion of the unit. The hydrophilic portion consists of a chain of predetermined length formed by polymerization of ethylene oxide molecules. The balance of the water-attracting and the water-repellent groups of the molecule accounts, of course, for its surface-active properties. I shall confine my observations, in general, to the chemotherapeutically active mixture, D2 (where n = 0, 1, 2, &c.; x = average of 20). Chemotherapeutic Tests These tests have, in general, been done using a standardized mouse test, a test that is now considered reliable for a preliminary assessment. The mice are infected intravenously with a virulent strain of human tubercle bacilli, H37Rv.
The mixture, D2, produced marked prolongation of life, and the degree of protection is comparable to that obtained with streptomycin. While we normally give four intravenous injections on the first, fourth, eighth and eleventh days after infection, a single injection one day, or even five days after infection gives as good therapeutic results. It should be remembered that the recognized antituberculous drugs, like streptomycin, are administered daily. While we use the intravenous route of therapy as the most effective routine test, the subcutaneous and intraperitoneal routes are also effective whereas feeding gives no protection.
The results with D2 in the mouse test indicated the drug had marked activity, and was therefore worth testing in the guinea-pig. A guinea-pig test is considered a more exacting test, and one that can, by manipulation, be used not only to assess-protection against a progressive infection but healing or regression of the established disease. In the guinea-pig test the infection was allowed to develop three weeks before treatment was started. The group of guinea-pigs on D2 was coitpared with streptomycin treated and untreated groups. Treatment was continued daily for sixty days and both drugs, this time, were given subcutaneously.
The streptomycin and detergent treated groups showed marked protection as compared with the untreated group and there was macroscopic and microscopic evidence of regression and healing. While the order of activity of the two drugs was similar, there was probably more residual active tuberculosis in the group on detergent than on streptomycin.
In contrast with the marked activity of D2 against tuberculosis in the adult animal it was found inactive when given to chick embryos infected with tubercle bacilli. It was equally inactive whether administered to the yolk sac, allantoic cavity or intravenously.
(We are indebted to Mr. G. E. Davies of Imperial Chemical (Pharmaceuticals) Ltd., for the chick embryo tests.) Toxicity Tests Acute intravenous toxicity tests with D2, showed that doses up to 75 mg. produced no immediate ill-effects. Chronic toxicity tests, on the other hand, all showed liver damage consisting of focal areas of cellular necrosis very variable in extent and distribution but unfortunately uniform. This can be produced by repeated dosing in mice and was present in the guinea-pigs referred to previously. It should therefore be stressed that the therapeutic dose level produces liver damage.
Blood levels.-Present rather insensitive methods for estimating the detergents have snown, none the less, that the drug remains in the blood stream for many hours, even days. No detergent has been found in the blood of mice after massive doses by mouth. 3
Blood and adrenal glands.-Large doses of the detergent given intravenously produce a marked lipaemia associated with 4-5 fold increase in the cholesterol level in the mouse, guinea-pig and rat. One other very interesting effect was that observed in the mouse adrenal gland following large doses intravenously. The glands were pale pink instead of the normal yellow colour. Such glands when stained with Scharlach R show the cortex to be completely stripped of lipoids and histochemical tests showed no detectable cholesterol in the cortex. A similar depletion of cholesterol and fat was found in the corpora lutea of mice after treatment with D2.
Discussion of the Possible Mechanism
These very promising in vivo results in the standard mouse and guinea-pig tests were obtained with a product that has little or no in vitro activity against the tubercle bacillus. The only direct effect of D2 on the tubercle bacillus that we have found is the physical one of facilitating its submerged and dispersed growth. But even dispersion in the test tube is not correlated with activity against tuberculosis in the body, since inactive as well as active members of our series can produce excellent dispersed growth. It follows that had these substances been submitted to routine screening of antituberculous drugs in vitro before animal tests, they would have been passed over, or rather classed as growth promoters. We are not even sure that surface activity is an essential. Certainly some of the inactive members of the series are as surface active as the chemotherapeutically active mixture D2, and, in fact, differ only from it in molecular size. On the other hand, lengthening the ethylene oxide chain length of D2, which decreases the surface activity, completely abolishes the antituberculous effect.
It is possible that the detergent although inactive in vitro was broken down in the body to produce a chemotherapeutically active compound. Many samples of blood were therefore taken fronY guinea-pigs and mice, following large and reoeated doses, and these were used to culture tubercle bacilli seeded on to glass slides, using a modified Pryce technique, but no inhibitory substance has been detected. This failure to find evidence of an active derivative in the blood does not, however, completely rule out the possibility that such a compound is slowly produced locally or remains intracellular.
Although not bacteriostatic or bactericidal, the drug might decrease the ability of the organism to invade, that is, decrease its virulence. Tubercle bacilli were therefore grown in medium containing the detergent for many generations before being used to infect mice. All such tests show these organisms to be at least as virulent as the parent strain, probably even more virulent. Mice infected with these organisms grown in detergent could also be protected by treatment with the same detergent, showing that growth in the drug had not made the organisms resistant to specific chemotherapy.
It is this lack of demonstrable direct activity on the tubercle bacilli that has naturally stimulated us to consider that the surface-active substance may act primarily on the host defence mechanism. Since doses lower than those required to produce lipxmia, cholesterolkmia or changes in the adrenal cortex or ovary, referred to earlier, are chemotherapeutically active, we consider these changes are probably not essential. The effect of these detergents on the phagocytic activity of macrophages and polymorphs have given no clear-cut positive results.
The only hint of action on the host is the depression of tuberculin hypersensitivity in guinea-pigs treated with D2, first noticed in the guinea-pig test mentioned previously. This phenomenon has now been studied in greater detail using BCG-sensitized guinea-pigs and carrying out quantitative tuberculin tests in detergent treated and untreated groups of guinea-pigs (Hart, Long and Rees, 1952) .
Such tests show that the chemotherapeutically active representatives of the series diminish tuberculin sensitivity whereas inactive members fail to do so. The degree of desensitization is comparable to that of cortisone, but the mode of action is different. Whether there is a causal connexion between desensitization and chemotherapeutic activity remains as yet unproven.
Conclusion
D2 possesses sufficient liver toxicity to exclude its use in man. New methods are being used to fractionate D2 into more active and/or less toxic products. Undoubtedly we are dealing with a new type of anti-tuberculous agent, and the elucidation of its mode of action, which appears to be through the host, might throw new light on the host-parasite relationship in tuberculosis. Dr. P. D'Arcy Hart: We have had many interesting contributions and I shall try to sum up their essential content as they appear to me. An outstanding trend is the conception that in tuberculosis the conditions are much more complex than a directly anti-bacterial agent behaving in vivo rather like in vitro, but that it is possible to tackle this complexity. Accordingly we have had a series of papers on the relationship: tubercle bacillus-body-drugs.
The elegant corneal technique described by Robson, while primarily useful for defining the characteristics (e.g. the duration) of the anti-tuberculous effects of different drugs alone and in combination, is also clearly a method for studying the natural history of tuberculosis on, in and with the eye. The superior effectiveness of streptomycin plus isoniazid has been well shown. This and other methods and observations are throwing light on the mechanisms of direct chemotherapeutic action. But we now have a case, provided by our own work at the National Institute for Medical Research, and described by Rees, which offers a challenge to any technique to explain its mechanism. For these anti-tuberculous surface-active agents appear to be innocuous to the bacillus in vitro, and their powerful anti-tuberculous effect would appear to be via the host-so far, however, we have obtained no definite clue as to how. Apart from calciferol on the peculiar condition of lupus vulgaris, this is, we believe, a novel case, but we have only to think of cortisone to remember how in recent years the notion of host susceptibility in tuberculosis has been strongly revived.
Another main trend in this discussion is provided by the contributions of Knox and of Mitchison, which remind us that in spite of the limitations of purely in vitro work, there is much to be learnt. This is shown, for example, by Knox's observations on the mechanism of the shifting end-point of inhibition of tubercle bacilli by isoniazid alone, on the effects of combination with streptomycin or PAS, and on the possible use of plate cultures of M. smegmatis as a clinical guide. For maximum usefulness of in vitro observations, a prerequisite is the standardization of techniques, as, for example, in sensitivity tests; this has been shown very clearly by Mitchison's work using material obtained by his bacteriological reference laboratory for the M.R.C. trials. His correlations, moreover, of the level of in vitro resistance of tubercle bacilli to isoniazid with in vivo experimental efficacy of this drug may be of great practical value. They stress the necessity of everyone meaning the same thing when they give detailed reports of in vitro resistance. J In conclusion, I carry away three general ideas. One is that each new drug brings with it its special problems and patterns, from a study of which we can get something fundamentally new. The second is that with the revival of interest in the importance of the host in anti-tuberculosis chemotherapy we have turned full circle; for before the period following the introduction of penicillin, streptomycin and other antibiotics and the consequenit tendency to simplification of the issue as a fight between drug and bacterium, most of us used to think almost exclusively in terms of the host, though in a vague sort of way-rest, sunlight, food, cod-liver oil and even gold therapy. The third idea follows from this rational revival and planned approach to chemotherapeutic needs: Is it too much to hope that some of the anti-tuberculous remedies of the future will result therefrom-tailormade, So to speak, to the body's requirements, instead of off-the-shelf from the empirical emporium?
Contribution by the late Dr. Marc Daniels and Dr. Wallace Fox Dr. Wallace Fox: The Medical Research Council's Tuberculosis Research Unit is at present co-ordinating a large-scale trial of isoniazid in pulmonary tuberculosis and analysing the results on behalf of the Tuberculosis Chemotherapy Trials Committee. The trial is being undertaken in 45 hospitals in 14 regions of England, Scotland and Wales, and a large number of clinicians, bacteriologists and pathologists are co-operating. Over 900 patients have already been admitted to the trial, and 400 of them have completed the required six months of observation.
Patients are admitted in three main disease groups-Group 1, acute rapidly progressiv; disease of recent onset; Group 2, other disease expected to respond to chemotherapy; and Group 3, disease expected to make only a limited response to chemotherapy. Cases intended for Group 1 are referred to a central panel of clinicians and, if accepted, admission to hospital is arranged within a fortnight. Patients for Groups 2 and 3 are mainly selected by the co-operating physicians from patients already under their care.
In order to be eligible for the trial a patient must be bacteriologically positive, as far as is known must not have drug-resistant organisms, and must have had no recent anti-tuberculosis chemotherapy. After acceptance, treatment is allocated from random selection lists, which are held confidentially by the Tuberculosis Research Unit. The treatment is prescribed for the first three months for patients in Groups 1 and 2 and for the whole six months for those in Group 3.
For each patient, progress reports are received after each of the first three months, and a final progress report and case summary at six months. The main items from these reports are recorded on special cards, one for each patient. The data are accumulated, and regular analyses of results are carried out.
The main differences between the present trial and the previous M.R.C. Chemotherapy trials are the rapid admission of a large number of cases, and the continual analysis of the data. There have been several important consequences: (1) The relative effectiveness of the different treatments can be closely followed; (2) results can be reported rapidly-an important point when conflicting claims on the efficacy of a treatment have been made; (3) a close liaison can be maintained with the clinicians since they can be kept informed of the current standing of the different treatments; (4) by taking advantage of the information that the trial itself yields, it is possible to stop the allocation of some treatments and to introduce others during the actual course of the trial. Thus, when the present trial began, the two main treatments allocated were streptomycin I gramme daily with PAS 20 grammes daily, and isoniazid 200 mg. daily. When it was found that bacterial resistance to isoniazid alone was occurring, a third treatment, streptomycin 1 gramme daily with isoniazid 200 mg. daily, was introduced into all three disease groups. When the importance and frequency of isoniazid resistance became apparent, the trial was again modified and the allocation of streptomycin with PAS, and of isoniazid alone was stopped completely. At present, a study is being made of the use of isoniazid 200 mg. daily in combination with one of 2 different dosages of streptomycin or one of 2 dosages of sodium PAS. This flexibility in the present trial is a definite advantage since it ensures that the available clinical material shall yield information as quickly as possible.
In conclusion, the present comparative trial demonstrates that a co-operative effort by a large number of clinicians and bacteriologists is a reliable and also a speedy method of answering the problems presented by a new form of anti-tuberculosis chemotherapy.
Professor J. W. Crofton: At the present time there are three main drugs available for the treatment of pulmonary tuberculosis, streptomycin, sodium para-aminosalicylate (PAS), and isoniazid, with terramycin as a possible accessory. The value of these drugs depends on the results of treatment, the emergence of drug resistance and the toxicity of the drug. The results of treatment are being considered by other speakers.
Drug Resistance
Streptomycin resistance.-It is well known that if patients are treated with streptomycin alone, resistant organisms emerge in a high proportion of patients. When a daily dose of 5 to 12 grammes of PAS is given together with streptomycin 1 gramme, the incidence of streptomycin resistance is reduced to 20-30% after three to four months' treatment (Tucker, 1949; Daniels and Bradford Hill, 1952) , and if the daily dose of PAS is raised to 20 grammes streptomycin-resistant organisms are found in only S to 10% (Daniels and Bradford Hill, 1952) . The incidence of streptomycin resistance can be further reduced by giving streptomycin twice a week but daily PAS remains essential. Preliminary evidence suggests that the use of isoniazid with streptomycin may effect an important reduction in the incidence of streptomycin resistance (Medical Research Council, 1952) . Terramycin also, in a dose of S grammes a day, has recently been shown greatly to reduce the incidence of streptomycinresistant organisms (Miller et al., 1952) .
PAS resistance.-A summary of some reports of the incidence of PAS resistance is given in has been doubted, but if, later, streptomycin is given with PAS to the same patient streptomycinresistant tubercle bacilli are probably as likely to emerge as if streptomycin were given alone. PAS should therefore never be given alone. There is a great reduction in the incidence of PAS resistance if streptomycin is given at the same time (Medical Research Council, 1950; Veterans Administration, 1951 There has also been a clear indication that patients whose organisms become resistant do less well. Preliminary evidence suggests that the incidence may be reduced by using streptomycin at the same time.
Terramycin resistance.-The available evidence suggests that terramycin resistance will not be very important .
Toxicity
Streptomycin toxicity.-There is a significant reduction in the number of painful injections if streptomycin sulphate is substituted for the more usual calcium chloride complex (McLeod and Somner, 1952) . Vestibular disturbances are much less common using 1 gramme a day (20-30 %) than using 2 grammes (60-80%) (Tucker, 1949) . There is further reduction to about 5% when streptomycin is given two or three times a week , and there is some evidence that the incidence may be lowered by giving antihistamine drugs prophylactically (Bignall et al., 1951) . Deafness is a negligible danger with streptomycin except when given intrathecally. But it is a real danger with dihydrostreptomycin, a danger which is greatly increased if the drug is used intrathecally (Shane and Laurie, 1950; van Goidsenhoven and Stevens, 1950; Bernard et al., 1950; O'Connor et al., 1951) . This risk outweighs the advantage of decreased vestibular damage and, in my view, dihydrostreptomycin should not be used except in some rare case of hypersensitivity to streptomycin in which desensitization has proved impossible and in which there is no cross-sensitivity to dihydrostreptomycin.
Hypersensitivity to streptomycin and PAS.-Hypersensitivity to either of these drugs is similar in its common manifestations and in its treatment. Fever, with or without a rash, is the most frequent reaction and commonly occurs within three weeks of starting treatment. Treatment should be stopped and, when the reaction has subsided, hypersensitivity should be tested by giving successively a half dose of each drug. Rash or fever occurs within an hour or two if the patient is hypersensitive. He may react to both drugs. Desensitization is usually effected without difficulty by giving a small initial dose, 0 1 gramme in the case of streptomycin or 0 5 gramme in the case of PAS, and increasing this daily over two to three weeks. PAS toxicity.-Nausea, vomiting or diarrhcea are the commonest effects, and the incidence increases with increase in the dose. Nausea can often be overcome by increasing the dose slowly or by taking the drug towards the end of a meal. The more one assumes that there will be no trouble the less trouble there is. Special preparations of PAS, designed to avoid gastro-intestinal upset, should be used with caution; in at least one of these we have found substantially reduced absorption of the drug. Jaundice is an occasional manifestation and is probably a hypersensitivity reaction; in most reported cases it has occurred after neglect of a warning fever. PAS has an antithyroid action similar to thiouracil and goitre may occur after prolonged administration. I have had two recent cases after some six months' administration. In both radio-iodine tests (Dr. J. A. Strong) have demonstrated the blocking of the thyroid's uptake of iodine, though neither had any lowering of basal metabolic rate; presumably the hypertrophied thyroid was succeeding in manufacturing adequate hormone. In one patient the enlarged thyroid returned to normal within a fortnight of stopping the drug, in the other the goitre disappeared after some three weeks of thyroid administration, in spite of continuing with PAS. Weakness and cardiac irregularities, associated with a low serum potassium, have been reported following the use of PAS (Cayley, 1950; Heard et al., 1950) . It is thought that, in most cases at any rate, this is due to liquorice used as a flavouring agent (Strong, 1951) .
Toxicity of isoniazid.-Drowsiness, insomnia, tremors of the legs, disturbances of the bowels and bladder, exaggerated deep reflexes and extensor plantar responses have been reported in patients taking isomnazid. In many cases the symptoms may have been iatrogenic and, on doses of 200 mg. a day or 3 mg. per kg. body-weight, no significant toxic effects have been noted in current trials. But if doses of 6 to 10 mg. per kg. are given it does seem that symptoms of peripheral neuritis, or even of mental upset, may occur (Linton et al., 1952) . The lower dose, which is highly effective clinically, is therefore to be recommended.
Toxicity of terramycin.-The main toxic effects of terramycin are gastro-intestinal. These were frequent in the patients of Miller et al. (1952) , who were treated with doses of 5 grammes a day.
The Use of the Different Chemotherapeutic Regimes in Pulmonary Tuberculosis
Many combinations of arugs, and many different dosages and rhythms of dosage, are now available.
Some of these are summarized in Table II , in which regimes on which satisfactory evidence is available are printed in italics. (1) Streptomycin alone: Contra-indicated.
(2) PAS alone: Contra-indicated.
(3) Izoniazid alone: Contra-indicated.
Streptomycin and PAS:
(1) Streptomycin 1 gramme daily with PAS 20 grammes daily: Of proved effectiveness. Great reduction in incidence of tubercle bacilli resistant to either drug.
(2) Streptomycin 1 gramme two or three times a week with PAS 20 grammes daily:
As effective, or almost as effective, as II (1). Probable further reduction in incidence of streptomycin resistance and of streptomycin toxicity. m. Streptomycin and Isoniazid:
(1) Streptomycin 1 gramme daily with isoniazid 200 mg. daily: Very effective.
Possibly low incidence of resistance to either drug.
(2) Streptomycin 1 gramme two or three times a week with isoniazid 200 mg. daily: Probably effective but incidence of isoniazid resistance not yet known. IV. PAS with Isoniazid:
(1) PAS 20 grammes daily with isoniazid 200 mg. daily: Under trial.
(2) PAS 10 grammes daily with isoniazid 200 mg. daily: Under trial.
(3) PAS 10-20 grammes daily with isoniazid 200 mg. twice a week: A possible regime if PAS does not prove to reduce substantially the incidence of isoniazid resistance when the latter is given daily.
V. Terramycin with Streptomycin:
Terramycin 5 grammes daily with streptomycin 2 grammes every third day: Great reduction in incidence of streptomycin resistance. VI. Terramycin and Isoniazid:
(1) Terramycin 5 grammes daily with isoniazid 200 mg. daily: Under trial.
(2) Terramycin 5 grammes daily with isoniazid 200 mg. two or three times a week.
Conclusions
Although streptomycin and isoniazid together may be slightly more effective than streptomycin and PAS, if the bacilli become resistant to one they will probably become resistant to the other and the patient will be deprived of the two most effective drugs. Until we know more both drugs should be given daily. This combination is justifiable if chemotherapy is likely to be the definitive treatment, for instance in cases with mild disease and without cavitation in which resistant organisms are unlikely to emerge. It is also justifiable if the patient is grossly intolerant of PAS, if the organisms are PAS resistant or if, because of previous treatment with PAS alone, they are likely to be so. More complicated cases are best treated with streptomycin and PAS in the first place, reserving isoniazid in case the organisms become streptomycin-resistant later. In desperately ill patients it may be justifiable to use all three drugs in the first place, but personally I prefer to withdraw isoniazid into reserve as soon as a response has been obtained.
Sir Clement Price Thomas: The evidence which has so far been given, results from carefully controlled and annotated experiments, and I am sure you will not expect a mere surgeon to rise to the heights of a statistical survey, but merely to give some clinical impressions of the use of these agents as they affect the surgical treatment of this disease. There seem to be three main effects achieved by antibiotic therapy, firstly the effect on the general manifestations of the disease, secondly the anatomico-pathological changes within the lesion, and thirdly the effect of the therapy on the endobronchial disease affecting the larger bronchi.
Brief consideration of the three factors is necessary. It is common knowledge that the toxic phenomena of the disease are quickly ameliorated under treatment. It is true to say that the improvement, which hitherto took many months of bed rest and supportive treatment, can now be achieved in as many weeks with antibiotics. It is of equal importance that the group of cases one used to designate as slipping chronics now scarcely exists, for it is exceedingly rare to fail to arrest the downward trend unless the patient's organisms have become resistant to the treatment. The local changes in the disease are in many cases nothing short of being remarkable. One suspects that these changes have a twofold origin, firstly the effect of treatment on the endobronchial disease in the smaller bronchi, and secondly the direct effect of the agents on the interstitial lesions themselves. The former effect is probably of more direct interest to the surgeon. Surgeons have been called upon, certainly up to recent times, to deal with cavitation which has failed to respond to medical means, for example bed rest and artificial pneumothorax. Basing the argument on the assumption that the majority of cavities persist because of a check valve action in the draining bronchi resulting from tuberculous endobronchitis, one beneficial effect of therapy is to decrease the endobronchial disease and thus allow free bronchial drainage throughout the whole respiratory phase, with a resulting decrease in the size or even closure of the cavity. There is, however, evidence to suggest that stenosis of the affected bronchi may occur, in this way producing either closure of the cavity, or, if the disease itself is not controlled, its exclusion from the remainder of the bronchial tree, leaving behind the stenosis either a blocked cavity or a localized tuberculous bronchiectasis.
The effect of therapy on the larger bronchi is of great importance. We have, in the last five or six years, become increasingly aware of the frequency with which involvement of the larger bronchi occurs in association with cavitated pulmonary tuberculosis. As far as one can judge, this was not of very serious import when we were content only to treat these cases by thoracoplasty, for there was evidence to support the contention that if the cavities were closed by such a procedure, then the endobronchial disease took care of itself.
Be that as it may, when we commenced to use resection for pulmonary tuberculosis, the importance of the state of the bronchus at the time of resection soon became evident. It is true to say that in some cases, the bronchus at the line of section will heal even when it is the seat of gross disease, but all will agree that the presence of active disease at this site enhances the risk of a bronchial fistula enormously, and no surgeon would willingly or knowingly undertake resection in the presence of active endobronchial disease except there were very cogent reasons for so doing. As with bronchi of smaller degree stenosis of the bronchus sometimes follows treatment, not infrequently quite rapidly and one has heard the remark that the treatment has caused the stenosis. This, of course, is not the case; stenosis will only occur when the bronchial wall, in addition to the mucosa and submucosa, has been involved in the disease and the stenosis results from the healing with fibrosis consequent upon the treatment. We are probably not sufficiently conversant as yet with the anatomical characteristics of these stenoses, or perhaps it is true to say that we are as yet unable to predetermine the type of stenosis which may be present. We do know that some are much more localized than others, and in certain cases the stenosis is the main factor in the patient's condition, the parenchymal lesions being almost negligible. This has tempted me on one occasion to resect the main bronchus and the upper lobe, joining the lower lobe bronchus on to the upper end of the main bronchus; the result of this procedure is still sub judice, but is encouraging.
These three main effects have altered the face of surgery for pulmonary tuberculosis in that the severe risk case is now seen much less commonly, and consequently patients submitted to operation are in a much better condition to withstand it. There can also be no doubt that resection of the lung for this disease has now become a commonplace and safe procedure, leading to more and more conservative procedures.
Surgeons heretofore have been very concerned about the amount of streptomycin patients had received before they were presented for surgery, this being based on the fear of resistant strains arising in the patient to be operated upon. We found that apart from resection the complication rate following operation was not minimized if these drugs were used over the operative period, but we also found that these complications when they did arise were quickly and satisfactorily rectified if the organisms remained sensitive to the agents exhibited; hence our desire was to treat these patients who were under treatment with antibiotics early before the risk of resistance could arise.
We have been informed that the combination of streptomycin and isoniazid decreases the risk of the development of resistance to both these substances. This changes the whole outlook of the disease, and a position of affairs will arise, which in fact has already arisen in part, where surgery will resolve itself into what may be loosely termed the surgery of anatomical deformity, resultant upon stenosis of either the larger or the smaller bronchi. Treatment with antibiotics will be carried on not merely for months but for anything up to two and a half years, and the, surgeon will then be called in to deal with stenosis of the larger bronchi either by resection or plastic repair, and with stenosis of the smaller bronchi by resection of the area of lung behind the block which has not completely resolved.
It is obvious that this line of treatment carries with it serious economic implications, and it is doubtful whether such a course can be followed in all cases. Economic pressure has all along been the factor which has made for compromise between the ideal and the expedient, and I have no doubt that this will continue to be the case for many years to come.
It is not overstating the case to say that at last we can see ahead some real hope of eventually controlling the problem of pulmonary tuberculosis, even if we cannot eradicate it.
Dr. Honor V. Smith:
Tuberculin in the Treatment of Tuberculous Meningitis and Other Conditions
The intrathecal injection of the Purified Protein Derivative of tuberculin (P.P.D.) in a sensitized subject provokes an acute inflammatory response in the C.S.F. which, without doubt, represents a true, specific, tuberculin reaction of the meninges (Swithinbank et al., 1953) . In cases of tuberculous meningitis treated with streptomycin such intrathecal reactions appear to be therapeutic (Smith and Vollum, 1950) . 37 proven cases of tuberculous meningitis have now been treated with streptomycin and tuberculin and observed for one year or longer. Since treatment with intrathecal tuberculin is hazardous, and as experience in its use was lacking, these 37 cases were specially selected as having a bad prognosis on streptomycin alone. The evidence that tuberculin has a place in treatment is drawn from the clinical findings, the pathological findings, and from the recovery rate.
Clinical Findings
Excluding those patients who are virtually moribund on admission and in whom it proves impossible even to prolong the natural course of the illness, the commonest time of death on streptomycin alone is during the third and fourth months of treatment . In such cases the course of the illness is fairly typical: patients enter a period of deadlock which, after weeks or months, is succeeded by sustained deterioration and death, often with a terminal rise in intracranial pressure.
Once this sustained deterioration begins then the prognosis on streptomycin alone becomes almost hopeless (Cairns and Smith, 1952) . Out of 18 cases in which tuberculin was withheld until this sustained deterioration had been clearly demonstrated-and which can therefore be classified as streptomycin failures-in 12, recovery followed the addition of tuberculin to the regime of treatment.
Pathological Findings
These recoveries are ascribed to resolution of the meningeal exudate under the influence of the tuberculin. After unsuccessful treatment with streptomycin the cardinal finding post mortem is a dense collar of tuberculous exudate surrounding the brain-stem (Smith et al., 1948; Daniel, 1949; Cairns and Smith, 1952) . By harbouring nests of tubercle bacilli this exudate helps to perpetuate the infection which, by virtue of its anatomical distribution, gives rise to the common communicating hydrocephalus. There are now several cases in which this hydrocephalus progressed steadily in spite of full treatment with streptomycin, to recede under the action of tuberculin.
The post-mortem findings in those cases in which death occurred after a series of intrathecal tuberculin reactions had been provoked, confirm the conclusion that the exudate had resolved. In fact the tuberculin appears to bring about a profound change in the reactions of the tissues, since where there is residual infection this no longer manifests itself as the familiar dense sheet of exudate, but as discrete tubercle formation. Recovery Rate Table I shows the results obtained in this group of 37 selected, unfavourable cases treated with streptomycin and tuberculin, compared with those obtained in unselected cases treated with streptomycin alone. Both series have been broken down according to the clinical condition of the patients when treatment was begun (M.R.C. Report, 1948) . In spite of the exclusion of all early, and therefore favourable, cases the results in the "Tuberculin" series are rather better than in the "Streptomycin" series as a whole. Even more direct evidence of the value of tuberculin is provided by the 12 recoveries in those 18 cases classed as streptomycin failures. Mode of Action The resolution of the exudate appears to be related to the actual intrathecal tuberculin reaction itself rather than to any desensitization effect. In those cases in which no reactions were obtained no definite clinical improvement was seen; nor did the autopsy findings differ significantly from those seen after treatment with streptomycin alone. There is now evidence that the focal tuberculin reaction is accompanied by intense hyperemia and cedema of the tuberculous lesion which presumably increases the access of the antibiotics to the site of infection, and also by liquefaction of caseous material (Ebert and Barclay, 1952) . Accordingly the aim of treatment is to produce a series of intrathecal tuberculin reactions as quickly and as safely as possible.
LimiYations of the Method
The most serious drawback of this method of treatment is its potential danger: incessant observation and some experience in its use are required if disaster is to be avoided. It demands ample laboratory facilities, as daily cell counts and protein estimations are obligatory. It cannot correct errors in the basic chemotherapy, nor, apparently, has it anything to offer-when tuberculin sensitivity. has been lost. Above all, it cannot renew the diseased blood vessels nor restore infarcted brain tissue. Early diagnosis is thus more important than ever.
Application of this Method to Other Varieties of Tuberculosis
A certain number of cases of tuberculosis other than meningitis have been treated with streptomycin and PAS and with intramuscular injections of tuberculin given in sufficient amounts to provoke a systemic reaction, and followed for a minimum period of a year. These cases were selected according to the following criteria: (1) the infection was proved to be tuberculous; (2) those expert in the field were satisfied that the prognosis on conventional methods of treatment was very bad (in 2 cases of pulmonary tuberculosis a departure was made from this after confidence in the safety of the method had been gained); (3) the organism was known to be sensitive to streptomycin at the onset of treatment. In spite of this a serious degree of resistance developed in 3 cases.
The results in these cases are presented with the greatest reservation. No claims are made beyond stating that the margin of safety proved very wide: no patient grew worse while on treatment, even in those cases in which streptomycin resistance developed.
Pulmonary Tuberculosis
Thirteen cases ofpulmonary tuberculosis have been treated in collaboration with Dr. W. Stobie. With 2 exceptions all had extensive disease with cavitation. Myco. tuberculosis was easily identified on direct films of sputum in every case but 2, and in these positive cultures were obtained. Three patients had tuberculosis meningitis and one had amyloid disease in addition to the pulmonary tuberculosis.
Two patients failed to improve. Both had previously been treated with streptomycin and in both cases the organisms developed a considerable degree of resistance to streptomycin while under treatment with tuberculin. In spite of this, the tuberculin reactions did not bring about any deterioration, clinically or radiologically. Four patients showed good clinical and radiological improvement, but as organisms could still be cultured from sputum or laryngeal swabs they are classed as partial failures. The rest ali showed satisfactory clinical and radiological improvement and cultures of laryngeal swabs became, and have remained, negative. Lupus Vulgaris 6 cases of lupus vulgaris were treated in collaboration with Dr. Alice Carleton. The length of history varied between 8 and 22 years. Calciferol had been given in every case and 2 patients had received streptomycin as well.
Treatment was limited to a six-weeks course. In all cases the lesions were clinically healed three months after treatment was concluded, though 3 have since showed small areas of reactivation.
Renal Tuberculosis
One case of renal tuberculosis has been treated in collaboration with Mr. Elliott-Smith. Nephrectomy had been performed five years previously and the patient was readmitted with the urine loaded with pus, blood and albumen. Tubercle bacilli were isolated on culture. Intravenous pyelography showed poor concentration in the remaining kidney but no gross deformity. The patient was discharged clinically well and with normal urine in May 1950, and has remained well. The urine is still normal. Conclusions
In view of the evidence here briefly summarized, it is concluded that in the treatment of tuberculous meningitis, tuberculin, when given in sufficient amounts to promote a reaction, potentiates the chemotherapy. Whether it can do so in the treatment of other forms of tuberculosis is not known, but nothing has yet been seen incompatible with this conclusion, and it is accordingly suggested that this method of treatment merits a planned, controlled trial.
Sir Geoffrey Marshall: The symposium was concluded by Sir Geoffrey Marshall, who emphasized that one of the most important problems in the chemotherapy of tuberculosis was the avoidance of drug resistance. On no account should any one of the antibiotics be used alone, as sooner or later resistant strains of bacilli would develop and then not only would that drug be of no further use to the patient either singly or in combination, but the patient would become a serious menace to the community as a potential source of infection with these resistant organisms. The speaker then continued: We have seen examples of infants infected by gtreptomycin-resistant tubercle bacilli who have developed tuberculous meningitis and who inevitably died as there was no effective remedy. When we can use these antibiotic drugs without fear of inducing bacterial resistance, we shall be able to employ them freely at an early stage of the disease, when the lesions are of recent origin and before the majority of the small vessels in their neighbourhood have become sclerosed. We shall then be able to kill the infecting agent before it has become inaccessible to drugs in the blood stream, and we shall be able to halt the disease before tissue damage has rendered it chronic.
